Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901037 | 0.85 | TBXA2R (0.40) | TBXA2RCYP19A1CNR1ACHECNR2 | |
| SCHEMBL16200825 | 0.83 | MAPT (0.40) | TBXA2RCYP19A1CNR1ACHECNR2 | |
| SCHEMBL6200633 | 0.83 | MMP2 (0.38) | CNR1CNR2KMT2AMAPTMEN1 | |
| SCHEMBL30804969 | 0.82 | CNR2 (0.34) | CNR1CNR2KMT2AMEN1ALDH1A1 | |
| SCHEMBL6202633 | 0.82 | ALDH1A1 (0.40) | TBXA2RCYP19A1CNR1KMT2AMAPT | |
| SCHEMBL6201097 | 0.80 | CNR1 (0.38) | CNR1CNR2ALDH1A1 | |
| SCHEMBL12196411 | 0.78 | CCR2 (0.36) | CYP19A1CNR1MAPTPOLBALDH1A1 | |
| SCHEMBL12196413 | 0.78 | CCR2 (0.36) | CYP19A1CNR1MAPTPOLBALDH1A1 | |
| SCHEMBL8204279 | 0.76 | ALDH1A1 (0.39) | TBXA2RCYP19A1CNR1KMT2AMAPT | |
| SCHEMBL28565640 | 0.75 | CYP19A1 (0.48) | CYP19A1CNR2KMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20170368085-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20160310518-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160310518-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2016-10-27 | — | — | US | disclosed |
| WO-2014144485-A9 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140275090-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275090-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271734-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. | 2014-09-18 | — | — | US | disclosed |
| US-20140271734-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. | 2014-09-18 | — | — | US | disclosed |
| US-20140243281-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | Lumena Pharmaceuticals, Inc. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20030232834-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | KELLER BRADLEY T (US) | 2003-12-18 | — | — | US | disclosed |
| WO-2003022804-A9 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | SEARLE LLC (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030199515-A1 | Method for the preparation of crystalline tetrahydrobenzothiepines | G.D. SEARLE, LLC (US) | 2003-10-23 | — | — | US | disclosed |
| US-6586434-B2 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE, LLC | 2003-07-01 | — | — | US | disclosed |
| WO-2003040127-A1 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | G.D. SEARLE LLC (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003022804-A2 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | G.D. SEARLE LLC (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1286984-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | Pharmacia Corporation (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020061888-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | G.D. SEARLE LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE LLC | 2002-03-14 | — | — | US | disclosed |
| WO-2001068637-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | TBXA2R 4035/4885CYP19A1 2563/4885CNR1 3830/4885 |
| US-20170368085-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | TBXA2R 4620/4885CYP19A1 1737/4885CNR1 4616/4885 |
| US-20030199515-A1 | Method for the preparation of crystalline tetrahydrobenzothiepines | TPMT, MPST, SULT1A1 | TBXA2R 2660/4885CYP19A1 2669/4885CNR1 3970/4885 |
| US-20030232834-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | TOP2A, TOP2B, TYMP | TBXA2R 2519/4885CYP19A1 2502/4885CNR1 2111/4885 |
| US-20140243281-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | TBXA2R 4653/4885CYP19A1 1809/4885CNR1 4479/4885 |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | TBXA2R 394/4885CYP19A1 1022/4885CNR1 1896/4885 |
| US-20140275090-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | SLC10A2, SLC10A1, ABCB11 | TBXA2R 3234/4885CYP19A1 3904/4885CNR1 3894/4885 |
| US-20140271734-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | SLC10A2, SLC10A1, ABCB11 | TBXA2R 2906/4885CYP19A1 4546/4885CNR1 4389/4885 |
| US-20020061888-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | SLC10A1, HMGCR, SLC10A2 | TBXA2R 3515/4885CYP19A1 1094/4885CNR1 2968/4885 |
| US-20160310518-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | TBXA2R 4620/4885CYP19A1 1737/4885CNR1 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.